Linno Pharmaceuticals, Inc.
Clinical trials sponsored by Linno Pharmaceuticals, Inc., explained in plain language.
-
New drug aims to control kidney disease in patients not helped by standard care
Disease control Not yet recruitingThis study tests an experimental drug called SLN12140 in 48 adults with IgA nephropathy, a kidney disease that is not well controlled with current treatments. Participants will receive either the drug or a placebo by injection for 36 weeks, and those who may benefit can continue …
Phase: PHASE2 • Sponsor: Linno Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 26, 2026 12:09 UTC
-
New hope for PNH: experimental drug SLN12140 enters phase II trial
Disease control Not yet recruitingThis study tests a new drug called SLN12140 in adults with paroxysmal nocturnal hemoglobinuria (PNH) who have never received complement inhibitor therapy. The goal is to see if the drug can reduce a key blood marker (LDH) by at least 60% and improve symptoms. Ten participants wil…
Phase: PHASE2 • Sponsor: Linno Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 26, 2026 12:04 UTC